Premium
MDA‐7/IL‐24 regulates proliferation, invasion and tumor cell radiosensitivity: A new cancer therapy?
Author(s) -
Dent Paul,
Yacoub Adly,
Grant Steven,
Curiel David T.,
Fisher Paul B.
Publication year - 2005
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.20502
Subject(s) - cytokine , cancer research , biology , suppression subtractive hybridization , endoplasmic reticulum , cancer cell , cell growth , cancer , microbiology and biotechnology , immunology , gene expression , biochemistry , gene , genetics , cdna library
The novel cytokine MDA‐7/IL‐24 was identified by subtractive hybridization in the mid‐1990s as a cytokine whose expression increased during the induction of terminal differentiation, and that was either not expressed or was present at low levels in tumor cells compared to non‐transformed cells. Multiple studies from several laboratories have subsequently demonstrated that expression of IL‐24 in tumor cells, but not in non‐transformed cells, causes their growth arrest and ultimately cell death. In addition, IL‐24 has been noted to be a radiosensitizing cytokine, which in part is due to the generation of reactive oxygen species (ROS) and causing endoplasmic reticulum stress. Recent publications of Phase I trial data have shown that a recombinant adenovirus to express MDA‐7/IL‐24 (Ad. mda ‐ 7 (INGN 241)) was safe and had tumoricidal effects in patients, which argues that IL‐24 may have therapeutic value. This review describes what is known about the impact of IL‐24 on tumor cell biology in addition to approaches that may enhance the toxicity of this novel cytokine. © 2005 Wiley‐Liss, Inc.